Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 64Nivolumab 57Ipilimumab 35Specimen Handling 24Magnetic Resonance Spectroscopy 21Cyclophosphamide 16Biopsy 13relatlimab 11binimetinib 11Opdualag 11CTLA-4 Antigen 11trametinib 10fludarabine 10Radiosurgery 10dabrafenib 8lifileucel 7fludarabine phosphate 7encorafenib 7aldesleukin 7atezolizumab 6Interleukin-2 6cemiplimab 5X-Rays 5Paclitaxel 5Immunoglobulin G 5Blood Specimen Collection 5Taxes 4Radiotherapy 4Pemetrexed 4Gemcitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Paroxetine × 90 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡